Table 6.
Clinical benefit by tumor subtypes and treatment line
| Characteristics | Clinical benefit N (%) |
P |
|---|---|---|
| Triple negative | ||
| Yes | 6 (23.1) | n.s. |
| Not | 30 (34.5) | |
| ER/PgR status | ||
| ER and/or PgR positive | 28 (33.3) | n.s. |
| ER and/or PgR negative | 12 (41.4) | |
| HER2 | ||
| Overexpressed/amplified | 6 (46.1) | n.s. |
| Not overexpressed/amplified | 32 (34.8) | |
| Dominant disease site | ||
| Visceral | 34 (40) | 0.07 |
| Non visceral | 6 (21.4) | |
| Metastatic disease site | ||
| 1 | 5 (27.8) | n.s. |
| ≥2 | 35 (36.8) | |
| Number of prior chemotherapy for advanced disease | ||
| 2 | 12 (35.3) | n.s. |
| ≥3 | 28 (35.4) |